Advertisement

International Journal of Hematology

, Volume 78, Issue 2, pp 133–138 | Cite as

Outcome of Adult Severe or Very Severe Aplastic Anemia Treated with Immunosuppressive Therapy Compared with Bone Marrow Transplantation: Multicenter Trial

  • Myung-Ju Ahn
  • Jung-Hye Choi
  • Young-Yeul Lee
  • Il-Young Choi
  • In-Soon Kim
  • Sung-Soo Yoon
  • Sun-Yang Park
  • Byung-Kook Kim
  • Cheolwon Suh
  • Hee Jeong Son
  • Cheol-Won Jung
  • Jae Hoon Lee
  • Ju-Myung Sung
  • Suck-Ah Im
  • Doyeun Oh
  • So-Young Jung
  • Hwi-Joong Yoon
  • Kyung-Sam Cho
  • Jung-Ae Lee
  • Young-Jin Yuh
  • Sung-Rok Kim
  • Moran Ki
Article

Abstract

To compare survival rates and long-term complications after bone marrow transplantation (BMT) or treatment with immunosuppressive agents (ISA) in the management of adult aplastic anemia (AA) and to identify prognostic factors associated with improved survival, we evaluated 229 adult AA patients treated with ISA from 1990 to 2001 and compared the results with those for 64 BMT recipients. Of 156 patients with severe aplastic anemia (SAA) or very severe AA treated with ISA (antithymocyte globulin [ATG]or ATG plus cyclosporine), 46.8% showed complete or partial response and 7.1% had relapses. After long-term follow-up, 1 case each of acute leukemia, myelodysplastic syndrome, and paroxysmal nocturnal hemoglobinuria developed.The 6-year survival rate was 69%. Response to ISA, disease severity, and low absolute neutrophil count (ANC) (≤200/mm3) were associated with poor survival. Patient age, sex, initial platelet count, etiology, or treatment regimen did not significantly affect survival. Cox regression analysis showed low ANC to be the only pretreatment variable significantly associated with poor survival (P = .000). Of 64 BMT recipients, 82.8% had sustained engraftment, and 12.5% experienced graft failure. Twenty (31.3%) of the patients developed grade II to IV acute graft-versus-host disease (GVHD), and 12 (18.8%) of the patients developed chronic GVHD.The 6-year survival rate was 79%. Patient age and sex, disease severity, etiology,ANC, initial platelet count, and treatment regimen did not affect survival. Survival of 83 AA patients, aged 14 to 40 years, treated with ISA was not statistically significant from that of 61 adult AA patients who underwent BMT (6-year survival rate, 65% and 79%, respectively). However, BMT in adult AA achieved long-term engraftment and a lower relapse rate than ISA.These results suggest that ISA can achieve a high response rate and long-term survival among patients with adult AA,regardless of disease severity. Further studies with larger numbers of patients and long-term follow-up are needed.

Key words

Adult aplastic anemia Immunosuppressive therapy Bone marrow transplantation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barrett AJ, Young NS. The treatment of severe acquired aplastic anemia.Blood. 1995;85:3367–3377.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Deeg HJ, Leisenring W, Storb R, et al. Long-term outcome after marrow transplantation for severe aplastic anemia.Blood. 1998;91:3637–3645.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Passweg JR, Socie G, Hinterberger W, et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved?Blood. 1997;90:858–864.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation: implications for cure.N Engl J Med. 1999;341:14–21.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial.N Engl J Med. 1983;308:113–118.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Doney K, Pepe M, Storb R, et al. Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-doe methylprednisolone, and oxymetholone.Blood. 1992;79:2566–2571.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Frickhofen N, Joachim PK, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group.N Engl J Med. 1991;324:1297–1304.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporine alone versus the combination of antithymocyte globulin and cyclosporine for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic AnemiaWorking Party.Blood. 1999;93:2191–2195.Google Scholar
  9. 9.
    McGlave PB, Haake R, Miller W, Kim T, Kersey J, Ramsay NK. Therapy of severe aplastic anemia in young adults and children with allogeneic bone marrow transplantation.Blood. 1987;70:1325–1330.PubMedGoogle Scholar
  10. 10.
    Sanders JE, Storb R, Anasetti C, et al. Marrow transplant for children with severe aplastic anemia.Am J Pediatr Hematol Oncol. 1994;16:43–49.PubMedGoogle Scholar
  11. 11.
    Kaplan EL, Meier P. Non-parametric estimation for incomplete observation.J Am Stat Assoc. 1958;53:457.CrossRefGoogle Scholar
  12. 12.
    Paquette RL, Tebyani N, Frane M, et al. Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation.Blood. 1995;85:283–290.PubMedGoogle Scholar
  13. 13.
    Doney K, Leisenring W, Storb R, Appelbaum FR. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy.Ann Intern Med. 1997;126:107–115.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Marsh JCW, Hows JM, Bryett KA, et al. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity.Blood. 1987;70:1046–1052.PubMedGoogle Scholar
  15. 15.
    Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation versus immunosuppression for the treatment of severe aplastic anemia (SAA): a report of the EBMT SAA Working Party.Br J Haematol. 1988;70:177–182.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Socie G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anemia Working Party.N Engl J Med. 1993;329:1152–1157.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2003

Authors and Affiliations

  • Myung-Ju Ahn
    • 1
  • Jung-Hye Choi
    • 1
  • Young-Yeul Lee
    • 1
  • Il-Young Choi
    • 1
  • In-Soon Kim
    • 1
  • Sung-Soo Yoon
    • 2
  • Sun-Yang Park
    • 2
  • Byung-Kook Kim
    • 2
  • Cheolwon Suh
    • 3
  • Hee Jeong Son
    • 3
  • Cheol-Won Jung
    • 4
  • Jae Hoon Lee
    • 5
  • Ju-Myung Sung
    • 6
  • Suck-Ah Im
    • 6
  • Doyeun Oh
    • 7
  • So-Young Jung
    • 7
  • Hwi-Joong Yoon
    • 8
  • Kyung-Sam Cho
    • 8
  • Jung-Ae Lee
    • 9
  • Young-Jin Yuh
    • 10
  • Sung-Rok Kim
    • 10
  • Moran Ki
    • 11
  1. 1.Departments of Internal MedicineHanyang UniversitySeoulKorea
  2. 2.Seoul National UniversityKorea
  3. 3.Ulsan UniversityKorea
  4. 4.Sungkyonkwan UniversityKorea
  5. 5.Kacheon UniversityKorea
  6. 6.Ewha UniversityKorea
  7. 7.Pundang CHA UniversityKorea
  8. 8.Kyung Hee UniversityKorea
  9. 9.Hallym UniversityKorea
  10. 10.Sanggye Paik HospitalKorea
  11. 11.Department of Preventive MedicineEulji University, College of MedicineSeoulKorea

Personalised recommendations